Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.53 |
| ▸ | MAX | P61244 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068176 | 1.00 | MYC (0.53) | MYCMAXKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL29231882 | 0.92 | MYC (0.50) | MYCMAXKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL31326400 | 0.89 | MYC (0.50) | MYCMAXKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL4652551 | 0.86 | MYC (0.44) | MYCMAXALDH1A1MERTKHTT | |
| SCHEMBL14348284 | 0.86 | MERTK (0.47) | MYCMAXALDH1A1MERTKAPP | |
| SCHEMBL30870967 | 0.83 | MYC (0.47) | MYCMAXL3MBTL1ALDH1A1MERTK | |
| SCHEMBL15507763 | 0.83 | MYC (0.47) | MYCMAXL3MBTL1ALDH1A1MERTK | |
| SCHEMBL4652365 | 0.83 | MYC (0.56) | MYCMAXKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL21494712 | 0.80 | PIN1 (0.55) | MYCMAXKDM4EALDH1A1MERTK | |
| SCHEMBL31528961 | 0.80 | MYC (0.45) | MYCMAXL3MBTL1ALDH1A1MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | NUTSHELL THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2025-07-15 | — | — | US | disclosed |
| CN-119350323-B | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025077783-A1 | DEUTERATED INDOLIZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海宇道生物技术有限公司 | 2025-04-17 | — | — | WO | disclosed |
| CN-119350323-A | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2025011684-A2 | N-SULFONAMIDE NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AND APPLICATION THEREOF | 上海宇道生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| WO-2014037750-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
| EP-1408986-B1 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7312246-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312246-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1408986-A4 | PROTEOMIMETIC COMPOUNDS AND METHODS | UNIV YALE (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050215563-A1 | Proteomimetic compounds and methods | YALE UNIVERSITY | 2005-09-29 | — | — | US | disclosed |
| US-6858600-B2 | Proteomimetic compounds and methods | YALE UNIVERSITY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1408986-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | MYC 1659/4885MAX 310/4885KDM4E 4750/4885 |
| US-12357634-B2 | 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy | IL2, THPO, IL6 | MYC 2305/4885MAX 4546/4885KDM4E 2175/4885 |
| US-20250304578-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | TP53, NPM1, TP53BP1 | MYC 59/4885MAX 1254/4885KDM4E 2338/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | MYC 28/4885MAX 2879/4885KDM4E 4363/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | MYC 3530/4885MAX 4810/4885KDM4E 858/4885 |
| US-12612402-B2 | Nitrogen-containing fused heterocyclic compounds of n-sulfonamide and use thereof | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NPM1 | MYC 497/4885MAX 2359/4885KDM4E 2905/4885 |
| US-20050215563-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | MYC 1659/4885MAX 310/4885KDM4E 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.